<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943590</url>
  </required_header>
  <id_info>
    <org_study_id>16-440</org_study_id>
    <nct_id>NCT02943590</nct_id>
  </id_info>
  <brief_title>STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)</brief_title>
  <official_title>STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will test whether atorvastatin, a drug commonly prescribed for reducing
      cholesterol levels, can protect the heart during chemotherapy with doxorubicin. Atorvastatin
      is from a family of medications that are commonly called &quot;statins&quot;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase II clinical trial. Phase II clinical trials test the
      effectiveness of a drug and determine whether the investigational drug works in treating a
      specific disease. &quot;Investigational&quot; means that the drug is being studied.

      The chemotherapy drug that the participant have been scheduled to be treated with,
      Doxorubicin, has been associated with the development of heart failure in some patients.

      This research study is testing whether Atorvastatin can protect the hearts of patients being
      treated with Doxorubicin and can reduce cardiac injury and the risk of heart failure.
      Atorvastatin is not approved by the FDA (the U.S. Food and Drug Administration) for use to
      reduce the cardiac injury after Doxorubicin. Atorvastatin is approved by the FDA for lowering
      cholesterol and for reducing the risk of heart attack and stroke. The heart is a muscle that
      pumps blood and Atorvastatin may protect the heart by preserving cardiac muscle function.

      The investigators will test whether atorvastatin protects the heart using a combination of
      imaging tests on the participants heart, blood tests, and stress testing. The imaging tests
      will involve an echocardiogram (an echo) and cardiac magnetic resonance (CMR), a type of
      magnetic resonance imaging (MRI) scan.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2017</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>12 months</time_frame>
    <description>To determine if statins preserve the LVEF at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac Events</measure>
    <time_frame>2 years</time_frame>
    <description>To determine whether statins reduce cardiac events (new onset heart failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Fibrosis</measure>
    <time_frame>6 months</time_frame>
    <description>To determine The Effect Of Statins On Myocardial Fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin T and Global Longitudinal Strain</measure>
    <time_frame>3 months</time_frame>
    <description>To determine whether changes in troponin T or global longitudinal strain by echocardiography at 3 months predict the reduction in LVEF at 12 months on MRI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A pill taken once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>A pill taken once a day</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years of age

          -  All patients with newly diagnosed NHL

          -  Scheduled to receive anthracycline-based therapy of the CHOP/RCHOP type

        Exclusion Criteria:

          -  Statin use or Statin use is indicated based on guidelines

          -  Pregnancy or breastfeeding

          -  Unable to provide informed consent

          -  Unexplained persistent elevation of transaminases (&gt;3 times upper limits of normal)

          -  Concomitant use of cyclosporine

          -  Renal failure: estimated glomerular filtration &lt;45 mL/min/1.73 m2

          -  Contraindication to a CMR (metallic object, severe claustrophobia, pacemaker, vascular
             clip

          -  LVEF of &lt;50% at baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas G Neilan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tomas G Neilan, MD</last_name>
    <phone>617-643-0239</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts general Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Neilan, MD</last_name>
      <phone>617-643-0239</phone>
    </contact>
    <investigator>
      <last_name>Tomas Neilan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Jacobsen, MD</last_name>
      <phone>617-632-4564</phone>
    </contact>
    <investigator>
      <last_name>Eric Jacobsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Tomas Neilan, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Cancer Treatment Related to Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

